Handa Pharmaceuticals (ROCO:6620) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6620 Handa Pharmaceuticals Inc ROCO:6620
76 GF Score
Price NT$80.80
GF Value NT$153.49
Valuation Significantly Undervalued
View Full Analysis

What is Handa Pharmaceuticals Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

ROCO:6620
76GF Score
Handa Pharmaceuticals Inc ROCO:6620
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Handa Pharmaceuticals (ROCO:6620) Overvalued in 2026?

Based on GuruFocus' analysis, Handa Pharmaceuticals stock appears to be undervalued. The current stock price of NT$80.80 is trading 47.4% below its estimated GF Value™ of NT$153.49. GuruFocus considers Handa Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for ROCO:6620:

  • Dividends Received:
  • GF Value™: NT$153.49 vs. price of NT$80.80 (47.4% below fair value)
  • GF Score™: 76/100

No single metric tells the full story. See the ROCO:6620 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Handa Pharmaceuticals Business Description

Address Nanke 3rd Road, 3F-1,3F-2, No.23, Xinshi Dist, Tainan, TWN, 74147
Handa Pharmaceuticals Inc is a Taiwan-based specialty pharmaceutical company. It is engaged in the development of niche drugs. The company focuses on the development of high-barrier/patentable niche products.
76GF Score

Get the complete analysis for ROCO:6620

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$80.80
Price
NT$153.49
GF Value